Peplin completes Neosil buy
Monday, 20 October, 2008
Peplin has completed its US$6.7 million purchase of private dermatology company Neosil.
The Brisbane biotech issued shares iin common stock in exchange for all equity interests in Neosil, which is developing a topical hair growth product and a broad-spectrum topical anti-microbial agent for acne.
Peplin shareholders have also approved a private placement of stock to raise US$24 million to help fund its Phase III trial of PEP005, a topical gel for sun spots.
Antibiotic for drug-resistant bacteria found in plain sight
The antibiotic in question is an intermediate chemical in the natural process that produces the...
No clear link between paracetamol in pregnancy and autism/ADHD
Existing evidence does not clearly link paracetamol (acetaminophen) use during pregnancy with...
Light at night can increase heart disease risk
Being exposed to bright light at night can significantly increase your chances of developing...
